Mark J. Ahn

Mark J.
Ahn was the founder of Talon Therapeutics, Inc. (founded in 2003) where he served as President & Chief Executive Officer from 2003 to 2007.
He was also the founder of Aroa Biosurgery Ltd. (founded in 2007) where he held the position of Director.
Currently, Dr. Ahn is a Director at Immusoft Corp., a Member-Governors Board at Chaminade University of Honolulu, and a Trustee at the University of South Africa (since 2010).
In his former positions, he served as President & Chief Executive Officer at Email Real Estate.com, Inc., President, Chief Executive Officer & Director at Galena Biopharma, Inc. (from 2012 to 2014), Vice Chairman at Abeona Therapeutics, Inc. (from 2015 to 2017), Senior Director-Immunology at Bristol Myers Squibb Co., Director at Essia Health, Inc., Director at TransMolecular, Inc., Director at Iovance Biotherapeutics, Inc. (from 2010 to 2011), and General Manager at Amgen, Inc. He also held the position of Vice President-Hematology & Corporate Officer at Genentech, Inc. (from 2001 to 2003), Associate Professor at Willamette University, and Principal at The Aspen Institute, Inc. Additionally, he was a Professor at Victoria University of Wellington (from 2007 to 2009) and Principal at Pukana Partners Ltd. Dr. Ahn's education includes a graduate degree from Victoria University, undergraduate and MBA degrees from Chaminade University of Honolulu, and a doctorate degree from the University of South Australia.